A trial sponsored by AP-HP and conducted by teams of Beaujon Hospital, AP-HP, Inserm and Université Paris Diderot was set up to establish an indicator that reflects the severity of liver disease in patients with cirrhosis. Coordinated by Professor Pierre-Emmanuel Rautou and Dr. Audrey Payancé the Hepatology Service of Beaujon Hospital, AP-HP, this study establishes that measurement microvesicles rate from liver and circulating in the blood greatly improves prediction of 6-month mortality of patients with cirrhosis.
This indicator would better choose treatments offer in patients with cirrhosis. These results, published in the journal Hepatology , also opening a reflection on the value of strategies to reduce the rates of these microvesicles in the blood of patients with cirrhosis.
